[{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Undisclosed"},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Phentermine","moa":"||Norepinephrine transporter","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Mayo Clinic"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Topiramate","moa":"Carbonic anhydrase II | Carbonic anhydrase IV | Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA||Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic kainate | Glutamate receptor ionotropic AMPA||Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase III","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Upsher-Smith Laboratories","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic kainate | Glutamate receptor ionotropic AMPA||Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase III","graph3":"Upsher-Smith Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Upsher-Smith Laboratories \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Upsher-Smith Laboratories \/ Undisclosed"},{"orgOrder":0,"company":"Shanghai Mental Health Center","sponsor":"Huadong Hospital | Shanghai Tongji Hospital | Shanghai General Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Shanghai Mental Health Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shanghai Mental Health Center \/ Huadong Hospital | Shanghai Tongji Hospital | Shanghai General Hospital","highestDevelopmentStatusID":"1","companyTruncated":"Shanghai Mental Health Center \/ Huadong Hospital | Shanghai Tongji Hospital | Shanghai General Hospital"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"SK Chemicals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase I","graph3":"SK Chemicals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Chemicals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SK Chemicals \/ Undisclosed"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"INDIA","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glenmark Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"University of Copenhagen","sponsor":"Pharmaceutical Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"University of Copenhagen","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Copenhagen \/ Pharmaceutical Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"University of Copenhagen \/ Pharmaceutical Research Institute"},{"orgOrder":0,"company":"GSK","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase I","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"GSK \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"GSK \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase I","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"University of Colorado, Denver \/ Merck & Co"},{"orgOrder":0,"company":"Centre for Addiction and Mental Health","sponsor":"Ontario Ministry of Health and Long Term Care","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"CANADA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Undisclosed","graph3":"Centre for Addiction and Mental Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Centre for Addiction and Mental Health \/ Ontario Ministry of Health and Long Term Care","highestDevelopmentStatusID":"1","companyTruncated":"Centre for Addiction and Mental Health \/ Ontario Ministry of Health and Long Term Care"},{"orgOrder":0,"company":"University of Minnesota","sponsor":"Supernus Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase II","graph3":"University of Minnesota","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Minnesota \/ Supernus Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University of Minnesota \/ Supernus Pharmaceuticals"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Undisclosed","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Eton Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Eton Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"National Institute on Alcohol Abuse and Alcoholism","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism","highestDevelopmentStatusID":"8","companyTruncated":"NYU Langone Health \/ National Institute on Alcohol Abuse and Alcoholism"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Phase I","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"NYU Langone Health","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Undisclosed","graph3":"NYU Langone Health","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NYU Langone Health \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"NYU Langone Health \/ Undisclosed"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Eikonoklastes Therapeutics","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Partnership","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Neurology","graph2":"Preclinical","graph3":"Eikonoklastes Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eikonoklastes Therapeutics \/ Forge Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Eikonoklastes Therapeutics \/ Forge Biologics"},{"orgOrder":0,"company":"South West Sydney Local Health District","sponsor":"National Health and Medical Research Council, Australia | University of Sydney","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Topiramate","moa":"Sodium channel alpha subunit | Glutamate receptor ionotropic kainate | Carbonic anhydrase II | Carbonic anhydrase IV | GABA-A receptor; anion channel | Glutamate receptor ionotropic AMPA","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"South West Sydney Local Health District","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney","highestDevelopmentStatusID":"10","companyTruncated":"South West Sydney Local Health District \/ National Health and Medical Research Council, Australia | University of Sydney"}]
Find Clinical Drug Pipeline Developments & Deals for [(1R,2S,6S,9R)-4,4,11,11-tetramethyl-3,5,7,10,12-pentaoxatricyclo[7.3.0.0?,?]dodecan-6-yl]methyl sulfamate
Details :
Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Details :
Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Details :
Qsymia (phentermine/topiramate) is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity.
Details :
Topamax-Generic (topiramate) is a GABA-A receptor; anion channel positive modulator, small molecule which is indicated for the treatment of epilepsy and migraine.
Details :
QSIVA is a combination of phentermine, a sympathomimetic amine anorectic and topiramate extended-release, an antiepileptic drug. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adul...
Details :
The partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Details :
The company’s 1st-in-class gene therapy ET-101 has been engineered to overexpress Caveolin-1, which organizes and regulates synaptic receptors essential for neuromuscular signaling and function.
Details :
Qudexy Xr is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Migraine Disorders.
Details :
The U.S. FDA has approved Topiramate Extended-Release Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, the generic version of Qudexy®1 XR Capsules, 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg, of Upsher-Smith Laboratories, LLC.
Details :
Marketing Application for ET-101 was submitted for monotherapy to treat primary general tonic-clonic seizures in patients at least two years old, adjunctive therapy for treatment of partial-onset seizures, and as preventative treatment of migraine in pat...
Reset All
